At the ASCO Annual meeting in Orlando Florida, Cougar Biotechnology, Inc. announced perliminary results from their ongoing Phase II clinical trials of their much discussed investigational drug abiraterone acetate (CB7630). The company released some preliminary encouraging data in three separate poster presentations. First, I want to tell you what abiraterone acetate is. In scientific jargon [...]
I compiled a list of trials that are activily recruiting men with hormone refractory prostate cancer (HRPC) who have also failed chemotherapy (taxotere). Being at this point in the disease process is by far the scariest time. We face the reality that there are no more approved treatments available to control the cancer. Clinical trials [...]
A known fact is that between 15% to 35% of men who have surgery as their primary treatment after diagnosis of prostate cancer will experience a biochemical recurrence (BCR). The authors of a presentation, Michael B. Williams, MD, et al. presented at the American Urological Association Mid-Atlantic Section - 67th Annual Meeting - October 1 [...]
Today the movie version of Maurice Sendak's 1963 children’s picture book, “Where the Wild Things Are” opens in theaters. When the book was first published, many people complained that it was too scary. Sendak’s response was simple, he said just don’t read it. Sometimes, whether you read a book or watch a movie is not [...]
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]